BCL2 and breast cancer: The study of Esparza-Lopez et al. (2022) demonstrated that primary BC cells with mesenchymal phenotype show activated IKK/IκBα/NF-κB signaling and upregulated Bcl-2 and Bcl-xL activities that are linked with the resistance to paclitaxel [90].